Wed, Jun 11, 8:06 PM (32 days ago)
**AEON Biopharma, Inc. (AEON, NYSE American) - 10-K/A Summary** **Amendment Overview:** AEON Biopharma, Inc. filed Amendment No. 1 on Form 10-K/A to supplement exhibits in its original 2024 Annual Report. The amendment includes: - Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation. - Amendment to Amended and Restated Bylaws. - Updated description of the quorum requirement for shareholder meetings. **Financial Condition and Market Position:** - Market value of voting and non-voting common equity held by non-affiliates: $17.0 million. - Outstanding shares of Class A common stock: 10,532,802. **Strategic Overview and Future Outlook:** - No changes to financial information or strategic outlook were made in this amendment. - The amendment does not reflect events occurring after the original filing date (March 24, 2025). **Risk Factors:** - No new risk factors were disclosed in this amendment. **Financial Performance (Not Updated in This Amendment):** - Revenue, net income, operating expenses, and earnings per share details are not updated in this amendment and should be referred to in the original 2024 Annual Report. **Conclusion:** This amendment is an exhibit-only filing with no changes to the original financial statements or strategic outlook. Investors should refer to the original 2024 Annual Report for comprehensive financial information.